Your Health, We Care
Release date: 2024-08-26 10:17:13 Recommended: 381
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive recommendation for the approval of toripalimab (brand name Loqtorzi). This medication is intended for the first-line treatment of patients with nasopharyngeal carcinoma and oesophageal squamous cell carcinoma.
Applicant: TMC Pharma (EU) Limited
Form: 240 mg concentrate for solution for infusion
Active Substance: Toripalimab (ATC code: L01FF13)
Mechanism: Toripalimab is a humanized monoclonal antibody that targets PD-1, a protein that, when activated, inhibits immune responses, including those against tumors. By blocking this pathway, toripalimab enhances the body's immune response against cancer cells.
Efficacy
Clinical studies have shown that Loqtorzi improves progression-free survival in patients with locally advanced nasopharyngeal carcinoma and advanced or metastatic oesophageal squamous cell carcinoma compared to standard treatments.
Common Side Effects
Include anaemia, leukopenia, neutropenia, thrombocytopenia, nausea, vomiting, decreased appetite, rash, fatigue, abnormal liver function tests, hypothyroidism, constipation, and neuropathy.
Nasopharyngeal Carcinoma
Loqtorzi, in combination with cisplatin and gemcitabine, is recommended for adult patients with recurrent, non-operable or non-treatable by radiotherapy, or metastatic nasopharyngeal carcinoma.
Oesophageal Squamous Cell Carcinoma
Loqtorzi, combined with cisplatin and paclitaxel, is recommended for adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Loqtorzi should be prescribed and monitored by physicians experienced in cancer treatment. Detailed guidelines will be included in the summary of product characteristics, which will be published after the marketing authorisation is officially granted by the European Commission.
A summary of the positive opinion is available, though the final decision by the Commission is expected within 67 days of the CHMP’s recommendation.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the r···【more】
Recommended：67Release date: 2025-12-17
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved nirap···【more】
Recommended：60Release date: 2025-12-15
The U.S. Food and Drug Administration (FDA) announced today that it has approved···【more】
Recommended：79Release date: 2025-12-10
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisoca···【more】
Recommended：74Release date: 2025-12-08
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full ap···【more】
Recommended：94Release date: 2025-12-04
Primary analysis data from the randomized, double-blind, placebo-controlled phas···【more】
Recommended：89Release date: 2025-12-01
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently mad···【more】
Recommended：461Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest incr···【more】
Recommended：365Release date: 2024-07-09
At a grand pharmaceutical exhibition held recently in Dubai, Lucius Company of L···【more】
Recommended：353Release date: 2024-07-09
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appoint···【more】
Recommended：362Release date: 2024-07-09
On October 19, 2023, the World Health Organization (WHO) conducted a comprehensi···【more】
Recommended：422Release date: 2024-07-09
At present, the competition in all walks of life is very fierce, especially in t···【more】
Recommended：283Release date: 2024-07-09
Here are some key points about Lucius Pharmaceutical:Lucius Pharmaceuticals has ···【more】
Recommended：476Release date: 2024-07-09
From the Black Sea, the most terrifying ocean on earth, to the Mediterranean Sea···【more】
Recommended：294Release date: 2024-07-09
